Literature DB >> 12842846

Grb2 is required for the development of neointima in response to vascular injury.

Shaosong Zhang1, Jie Ren, M Faisal Khan, Alec M Cheng, Dana Abendschein, Anthony J Muslin.   

Abstract

OBJECTIVE: Neointima formation occurs in arteries in response to mechanical or chemical injury and is responsible for substantial morbidity. In this work, the role of the intracellular linker protein Grb2 in the pathogenesis of neointima formation was examined. Grb2 is a critical signaling protein that facilitates the activation of the small GTPase ras by receptor tyrosine kinases. METHODS AND
RESULTS: Cultured rat aortic smooth muscle cells were treated with an antisense morpholino to Grb2 and these cells showed a reduced proliferative response to platelet-derived growth factor stimulation. Grb2-/- mice do not survive embryonic development. Grb2+/- mice appear normal at birth and are fertile but have defective signaling in several tissues. Cultured smooth muscle cells derived from Grb2+/- mice grew at a much slower rate than cells derived from Grb2+/+ mice. Grb2+/- and Grb2+/+ mice were subjected to carotid injury. After 21 days, Grb2+/+ mice developed robust neointima formation that, in some cases, resulted in an occlusive lesion. In contrast, Grb2+/- mice were resistant to the development of neointima
CONCLUSIONS: Grb2 is an essential component of the signaling cascade resulting in neointima formation after arterial injury.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842846     DOI: 10.1161/01.ATV.0000085015.49110.85

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Regulation of vascular smooth muscle cell growth: targeting the final common pathway.

Authors:  Angela M Taylor; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-01       Impact factor: 8.311

2.  Bioinformatic Analysis of Coronary Disease Associated SNPs and Genes to Identify Proteins Potentially Involved in the Pathogenesis of Atherosclerosis.

Authors:  Chunhong Mao; Timothy D Howard; Dan Sullivan; Zongming Fu; Guoqiang Yu; Sarah J Parker; Rebecca Will; Richard S Vander Heide; Yue Wang; James Hixson; Jennifer Van Eyk; David M Herrington
Journal:  J Proteom Genom Res       Date:  2017-03-04

3.  Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway.

Authors:  Elisabeth A Lasater; Waylan K Bessler; Laura E Mead; Whitney E Horn; D Wade Clapp; Simon J Conway; David A Ingram; Fang Li
Journal:  Hum Mol Genet       Date:  2008-04-28       Impact factor: 6.150

4.  Deletion of Methionine Sulfoxide Reductase A Does Not Affect Atherothrombosis but Promotes Neointimal Hyperplasia and Extracellular Signal-Regulated Kinase 1/2 Signaling.

Authors:  Paula J Klutho; Steven M Pennington; Jason A Scott; Katina M Wilson; Sean X Gu; Prakash Doddapattar; Litao Xie; Ashlee N Venema; Linda J Zhu; Anil K Chauhan; Steven R Lentz; Isabella M Grumbach
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-08       Impact factor: 8.311

5.  Requirement for p38 mitogen-activated protein kinase activity in neointima formation after vascular injury.

Authors:  Brandon M Proctor; Xiaohua Jin; Traian S Lupu; Louis J Muglia; Clay F Semenkovich; Anthony J Muslin
Journal:  Circulation       Date:  2008-07-21       Impact factor: 29.690

Review 6.  MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets.

Authors:  Anthony J Muslin
Journal:  Clin Sci (Lond)       Date:  2008-10       Impact factor: 6.124

7.  Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach.

Authors:  Alexis Régent; Hanadi Dib; Kim H Ly; Christian Agard; Mathieu C Tamby; Nicolas Tamas; Babette Weksler; Christian Federici; Cédric Broussard; Loïc Guillevin; Luc Mouthon
Journal:  Arthritis Res Ther       Date:  2011-06-28       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.